Zanamivir hydrate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581075

CAS#: 551942-41-7 (hydrate)

Description: Zanamivir hydrate is neuraminidase inhibitors (NAIs) and is used worldwide for treatment and prophylaxis of influenza caused by influenza A and B viruses.

Price and Availability

Size Price Shipping out time Quantity
100mg USD 400 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-29. Prices are subject to change without notice.

Zanamivir hydrate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 581075
Name: Zanamivir hydrate
CAS#: 551942-41-7 (hydrate)
Chemical Formula: C12H22N4O8
Exact Mass: 350.1438
Molecular Weight: 350.33
Elemental Analysis: C, 41.14; H, 6.33; N, 15.99; O, 36.53

Related CAS #: 139110-80-8 (free base)   551942-41-7 (hydrate)  

Synonym: Zanamivir hydrate; D01937; J1.917.534K;

IUPAC/Chemical Name: (+)-(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((1R,2R)-1,2,3- trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid hydrate


InChi Code: InChI=1S/C12H20N4O7.H2O/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17;/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16);1H2/t5-,6+,8+,9+,10+;/m0./s1

SMILES Code: O=C(C1=C[C@H](NC(N)=N)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1)O.[H]O[H]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T.
Zanamivir for influenza in adults and children: systematic review of clinical
study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2547. doi:
10.1136/bmj.g2547. Review. PubMed PMID: 24811412; PubMed Central PMCID:

2: Pizzorno A, Abed Y, Rhéaume C, Boivin G. Oseltamivir-zanamivir combination
therapy is not superior to zanamivir monotherapy in mice infected with influenza
A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res. 2014 May;105:54-8. doi:
10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28. PubMed PMID: 24583158.

3: Chan-Tack KM, Kim C, Moruf A, Birnkrant DB. Clinical experience with
intravenous zanamivir under an Emergency IND program in the United States
(2011-2014). Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb
10. Review. PubMed PMID: 25667992.

4: Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome
following maternal use of zanamivir or oseltamivir during the 2009 influenza
A/H1N1 pandemic: a national prospective surveillance study. BJOG. 2014
Jun;121(7):901-6. doi: 10.1111/1471-0528.12640. Epub 2014 Mar 7. PubMed PMID:

5: Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL,
Crawford S, Smee DF, Tucker SP. A zanamivir dimer with prophylactic and enhanced
therapeutic activity against influenza viruses. J Antimicrob Chemother. 2014
Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28. PubMed PMID:
24777908; PubMed Central PMCID: PMC4100710.

6: Yang Y, Yang Z, Ren Y, Mei X. Effects of formulation and operating variables
on zanamivir dry powder inhalation characteristics and aerosolization
performance. Drug Deliv. 2014 Sep;21(6):480-6. doi: 10.3109/10717544.2014.883113.
Epub 2014 Feb 4. PubMed PMID: 24491208.

7: Sato M, Honzumi K, Sato T, Hashimoto K, Watanabe M, Miyazaki K, Kawasaki Y,
Hosoya M. Sequential influenza B viral load and susceptibility in children
treated with oseltamivir and zanamivir. Pediatr Infect Dis J. 2014
Jul;33(7):e168-72. doi: 10.1097/INF.0000000000000266. PubMed PMID: 24445826.

8: Lou Y, Gan J, Peppercorn A, Gould E, Weller S, Piscitelli SC, Patel P. Effect
of intravenous zanamivir on cardiac repolarization. Pharmacotherapy. 2013
Jul;33(7):701-9. doi: 10.1002/phar.1261. Epub 2013 Apr 3. PubMed PMID: 23553534.

9: Marty FM, Man CY, van der Horst C, Francois B, Garot D, Mánez R, Thamlikitkul
V, Lorente JA, Alvarez-Lerma F, Brealey D, Zhao HH, Weller S, Yates PJ,
Peppercorn AF. Safety and pharmacokinetics of intravenous zanamivir treatment in
hospitalized adults with influenza: an open-label, multicenter, single-arm, phase
II study. J Infect Dis. 2014 Feb 15;209(4):542-50. doi: 10.1093/infdis/jit467.
Epub 2013 Aug 27. PubMed PMID: 23983212; PubMed Central PMCID: PMC4047294.

10: Tian J, Zhong J, Li Y, Ma D. Organocatalytic and scalable synthesis of the
anti-influenza drugs zanamivir, laninamivir, and CS-8958. Angew Chem Int Ed Engl.
2014 Dec 8;53(50):13885-8. doi: 10.1002/anie.201408138. Epub 2014 Oct 14. PubMed
PMID: 25314609.

11: Shanmugam S. Zanamivir oral delivery: possibilities revisited. Ther Deliv.
2015;6(4):403-5. doi: 10.4155/tde.15.9. PubMed PMID: 25996038.

12: Weight AK, Belser JA, Tumpey TM, Chen J, Klibanov AM. Zanamivir conjugated to
poly-L-glutamine is much more active against influenza viruses in mice and
ferrets than the drug itself. Pharm Res. 2014 Feb;31(2):466-74. doi:
10.1007/s11095-013-1175-4. Epub 2013 Sep 25. PubMed PMID: 24065587; PubMed
Central PMCID: PMC3964776.

13: Shi LL, Cao Y, Zhu XY, Cui JH, Cao QR. Optimization of process variables of
zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular
transport in Caco-2 cell model. Int J Pharm. 2015 Jan 15;478(1):60-9. doi:
10.1016/j.ijpharm.2014.11.017. Epub 2014 Nov 12. PubMed PMID: 25448568.

14: Weller S, Jones LS, Lou Y, Peppercorn A, Ng-Cashin J. Pharmacokinetics of
zanamivir following intravenous administration to subjects with and without renal
impairment. Antimicrob Agents Chemother. 2013 Jul;57(7):2967-71. doi:
10.1128/AAC.02330-12. Epub 2013 Apr 15. PubMed PMID: 23587959; PubMed Central
PMCID: PMC3697365.

15: Zonja B, Gonçalves C, Pérez S, Delgado A, Petrovic M, Alpendurada MF, Barceló
D. Evaluation of the phototransformation of the antiviral zanamivir in surface
waters through identification of transformation products. J Hazard Mater. 2014
Jan 30;265:296-304. doi: 10.1016/j.jhazmat.2013.10.008. Epub 2013 Oct 24. PubMed
PMID: 24211180.

16: Coleman BL, Fadel SA, Drews SJ, Hatchette TF, McGeer AJ. Zanamivir versus
trivalent split virus influenza vaccine: a pilot randomized trial. Influenza
Other Respir Viruses. 2015 Mar;9(2):78-84. doi: 10.1111/irv.12301. Epub 2015 Jan
4. PubMed PMID: 25557838; PubMed Central PMCID: PMC4353320.

17: Schade D, Kotthaus J, Riebling L, Kotthaus J, Müller-Fielitz H, Raasch W,
Hoffmann A, Schmidtke M, Clement B. Zanamivir Amidoxime- and
N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
J Pharm Sci. 2015 Sep;104(9):3208-19. doi: 10.1002/jps.24508. Epub 2015 Jun 2.
PubMed PMID: 26037932.

18: Morokutti-Kurz M, König-Schuster M, Koller C, Graf C, Graf P, Kirchoff N,
Reutterer B, Seifert JM, Unger H, Grassauer A, Prieschl-Grassauer E, Nakowitsch
S. The Intranasal Application of Zanamivir and Carrageenan Is Synergistically
Active against Influenza A Virus in the Murine Model. PLoS One. 2015 Jun
8;10(6):e0128794. doi: 10.1371/journal.pone.0128794. eCollection 2015. PubMed
PMID: 26053018; PubMed Central PMCID: PMC4459876.

19: Shida Y, Hara K, Nohda S, Soutome T, Hirama T. The pharmacokinetic and safety
profiles of zanamivir after single and repeat intravenous administration in
healthy Japanese males. J Clin Pharm Ther. 2013 Jun;38(3):236-40. doi:
10.1111/jcpt.12056. Epub 2013 Mar 14. PubMed PMID: 23489210.

20: Thai KM, Le DP, Tran NV, Nguyen TT, Tran TD, Le MT. Computational assay of
Zanamivir binding affinity with original and mutant influenza neuraminidase 9
using molecular docking. J Theor Biol. 2015 Nov 21;385:31-9. doi:
10.1016/j.jtbi.2015.08.019. Epub 2015 Sep 1. PubMed PMID: 26341387.